AI Article Synopsis

  • Bpc species are Gram-negative bacteria causing diseases like melioidosis and glanders, with recent advances in vaccine development focusing on subunit and glycoconjugate vaccines.
  • The Bcc species, a second group of pathogenic bacteria, mainly affects those with weakened immune systems and has limited vaccine development efforts.
  • This review aims to evaluate the protective efficacy of various Bpc antigens, their study limitations, and whether these antigens could be used in a broader vaccine to protect against both Bpc and Bcc bacterial infections.

Article Abstract

are a group of Gram-negative bacteria that can cause a variety of diseases in at-risk populations. and , the etiological agents of melioidosis and glanders, respectively, are the two clinically relevant members of the complex (Bpc). The development of vaccines against Bpc species has been accelerated in recent years, resulting in numerous promising subunits and glycoconjugate vaccines incorporating a variety of antigens. However, a second group of pathogenic species exists known as the complex (Bcc), a group of opportunistic bacteria which tend to affect individuals with weakened immunity or cystic fibrosis. To date, there have been few attempts to develop vaccines to Bcc species. Therefore, the primary goal of this review is to provide a broad overview of the various subunit antigens that have been tested in Bpc species, their protective efficacy, study limitations, and known or suspected mechanisms of protection. Then, we assess the reviewed Bpc antigens for their amino acid sequence conservation to homologous proteins found in Bcc species. We propose that protective Bpc antigens with a high degree of Bpc-to-Bcc sequence conservation could serve as components of a pan- vaccine capable of protecting against both disease-causing groups.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10975474PMC
http://dx.doi.org/10.3390/vaccines12030313DOI Listing

Publication Analysis

Top Keywords

glycoconjugate vaccines
8
bpc species
8
bcc species
8
bpc antigens
8
sequence conservation
8
bpc
5
species
5
complex
4
complex subunit
4
subunit glycoconjugate
4

Similar Publications

FcRn-guided antigen trafficking enhances cancer vaccine efficacy.

Cancer Immunol Immunother

January 2025

Department of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, People's Republic of China.

The development of tumor vaccines represents a significant focus within cancer therapeutics research. Nonetheless, the efficiency of antigen presentation in tumor vaccine remains suboptimal. We introduce an innovative mRNA-lipid nanoparticle platform designed to express tumor antigenic epitopes fused with the transmembrane domain and cytoplasmic tail of the neonatal Fc receptor (FcRn).

View Article and Find Full Text PDF

Background: Recent advances in Alzheimer's disease (AD) therapeutics involve immunization against amyloid-β (Aβ). Post-mortem brain analysis from the first active Aβ immunotherapy trial indicated clearance of Aβ in some AD patients. Yet, the mechanisms regulating Aβ clearance following immunization remain unknown.

View Article and Find Full Text PDF

Herpes Simplex virus (HSV) is the cause of genital herpes and no prophylactic treatment is currently available. Replication-incompetent adenoviral vectors are potent inducers of humoral and cellular immune responses in humans. We have designed an adenoviral vector type 35 (Ad35)-based vaccine encoding the HSV-2 major surface antigen gD2 (Ad35.

View Article and Find Full Text PDF

In silico identification and ex vivo evaluation of Toxoplasma gondii peptides restricted to HLA-A*02, HLA-A*24 and HLA-B*35 alleles in human PBMC from a Colombian population.

Med Microbiol Immunol

December 2024

Grupo de Estudio en Parasitología Molecular (GEPAMOL), Faculty of Health Sciences, Centro de Investigaciones Biomédicas, Universidad del Quindío, Quindio, Armenia, Colombia.

Toxoplasma gondii infects approximately 30% of the population, and there is currently no approved vaccine. Identifying immunogenic peptides with high affinity to different HLA molecules is a promising vaccine strategy. This study used an in silico approach using artificial neural networks to identify T.

View Article and Find Full Text PDF

Immune checkpoint inhibitors (ICI) represent new anticancer agents and have been used worldwide. However, ICI can potentially induce life-threatening severe cutaneous adverse reaction (SCAR), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), hindering continuous ICI therapy. We examine 6 cohorts including 25 ICI-induced SJS/TEN patients and conduct single-cell RNA sequencing (scRNA-seq) analysis, which shows overexpression of macrophage-derived CXCL10 that recruits CXCR3 cytotoxic T lymphocytes (CTL) in blister cells from ICI-SJS/TEN skin lesions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!